Effect of Spironolactone and dbcAMP-Ca Combination Therapy on Clinical Outcomes and Left Ventricular Function in Chronic Heart Failure Patients Post Percutaneous Coronary Intervention

CONCLUSIONS: The combination therapy of spironolactone and dbcAMP-Ca holds potential as an effective treatment strategy for CHF patients following PCI. This combination therapy demonstrated superior clinical efficacy, improved left ventricular function, and enhanced autonomic nerve function, with reduced adverse reactions and biomarker levels. Spironolactone combined with dbcAMP-Ca can be considered as a beneficial treatment strategy for CHF patients post-PCI. The demonstrated clinical efficacy, improvement in left ventricular function, and enhanced autonomic nerve function support the wider application of this combination therapy in the management of CHF patients in clinical settings.PMID:38551427
Source: Alternative Therapies in Health and Medicine - Category: Complementary Medicine Authors: Source Type: research